Virinchi slips to ₹2.1 Cr consolidated loss as healthcare unit implodes; SaaS core solid
PAT -667.4% YoY · revenue -12.04% · margins compressing
₹70.13 Cr
-12.04% YoY
₹-2.1 Cr
-667.4% YoY
-2.99%
-3.5pp YoY
₹0.04
Virinchi's consolidated Q1 FY27 revenue fell 12.0% YoY to ₹70.13 Cr (from ₹79.74 Cr), though it rose 6.3% QoQ from Q4 FY26's ₹65.97 Cr. The group swung from a pretax profit of ₹2.87 Cr a year ago to a pretax loss of ₹6.44 Cr, and the reported net loss (before minority interest) was ₹2.10 Cr versus a ₹0.37 Cr profit in Q1 FY26 — a clear YoY deterioration at the consolidated level, the primary basis for this filing.
Q1 FY-2027 vs prior quarters
The swing was driven almost entirely by the Health Care Services segment, whose revenue nearly halved to ₹17.11 Cr (-38.8% YoY, from ₹27.96 Cr) and whose segment result flipped from a ₹4.01 Cr profit to a ₹7.98 Cr loss. Payment & Credit Services (India fintech) stayed loss-making too, widening marginally to ₹0.95 Cr from ₹0.88 Cr. A ₹4.34 Cr net tax credit — largely a deferred-tax benefit — cushioned the bottom line, narrowing the reported net loss to ₹2.10 Cr from the ₹6.44 Cr pretax loss. Non-controlling interests then absorbed ₹2.58 Cr of that group loss (tied to the healthcare subsidiaries, where Virinchi holds controlling but not full stakes), leaving equity holders of the parent with a marginal ₹0.48 Cr profit and EPS flat at ₹0.04 versus ₹0.43 Cr/₹0.04 a year ago. That owners'-level figure is the number that will read as 'profit' but is a function of loss allocation, not of improved group economics — the group itself made a loss this quarter that it did not make a year ago.
The stock went into the print at ₹15.27, down 2.4% over the past month of trading.
The standalone entity — mainly the SaaS Business (US fintech) — held up better on revenue, up 11.9% YoY to ₹44.84 Cr, and the SaaS segment's own profit grew 19.4% YoY to ₹9.66 Cr. But standalone PAT still fell 36.7% YoY to ₹3.88 Cr as administrative expenditure jumped 53.8% YoY (₹13.30 Cr to ₹20.45 Cr), compressing standalone net margin to 8.7% from 15.3% — cost inflation ate into the one segment that grew. There is no prior management guidance on record for this quarter, and no analyst/street estimates turned up in a search, so vs-guidance and vs-street both read as unknown; no management press release was available to cross-check against the print. During the quarter the company also allotted 39.10 lakh shares on warrant conversion, lifting paid-up capital to ₹112.71 Cr from ₹108.80 Cr.
W1
Newly board-approved Healthcare Business Acquisition (July 9, 2026) — watch consolidation timing and whether it addresses the existing ₹7.98 Cr segment loss
W2
Health Care Services segment trajectory — revenue nearly halved YoY to ₹17.11 Cr and swung to loss; watch for stabilization next quarter
W3
Standalone administrative cost trend — +53.8% YoY compressed standalone NPM to 8.7% from 15.3%; watch whether this normalizes
Figures converted from Rs. Lacs to Rs. Cr. Consolidated PAT (-2.10 Cr) is the 'Net Profit After Tax (VI-VII)' row, before minority interest; NCI absorbed a larger loss of -2.58 Cr, leaving profit attributable to parent owners of +0.48 Cr (matches reported EPS 0.04). No exceptional/prior-period items this quarter or in the YoY base quarter (Q1 FY26); Q4 FY26 comparative carried a one-off 5.30 Cr prior-period charge, relevant only to the QoQ comparison.